Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a valuable class of drugs in the management of type 2 diabetes mellitus. These agents replicate the actions of naturally occurring GLP-1, promoting insulin secretion and inhibiting glucagon release. Recent studies have yielded a diverse range of novel GLP-1 receptor agonists with imp

GLP-1 receptor activators are emerging as a groundbreaking strategy in the management of diabetes. These innovative medications mimic the actions of naturally occurring glucagon-like peptide-1 (GLP-1), a hormone that plays a crucial role in regulating blood sugar levels. By activating GLP-1 receptors, these drugs enhance insulin release from the pa